Skip to content

Mescaline: all studies

Page 45 of 97: studies 441 to 450 of 963, newest first. Back to the mescaline overview

Research

Identity and healing in three Navajo religious traditions: sa'ah naagháí bik'eh hózh [symbol: see text].

Medical Anthropology Quarterly December 1, 2000 E L Lewton, V Bydone

In this article, we elucidate how the Navajo synthetic principle sa'ah naagháí bik'eh hózh [symbol: see text] (SNBH) is understood, demonstrated, and elaborated in three different Navajo healing traditions. We conducted interviews with Navajo healers and their patients affiliated with Traditional Navajo religion, the Native American Church, and Pentecostal Christianity. Their narratives provide...

Rethinking the role of diagnosis in Navajo religious healing.

Medical Anthropology Quarterly December 1, 2000 D Milne, W Howard

Diagnosis plays a central, primary role in the therapeutic process across cultures. In this article, the authors examine the role of diagnosis in two Navajo religious healing traditions, the Traditional Navajo religion and the Native American Church (NAC), and examine a case study of a diagnostic encounter between an NAC diagnostician and a Traditional patient. The authors assert that, for...

Parkinsonism after Taking Ecstasy

New England Journal of Medicine May 6, 1999 Scott Mintzer, Susan L. Hickenbottom, Sid Gilman 56 citations

To the Editor: Recreational use of 3,4-methylenedioxymethamphetamine (MDMA, or “ecstasy”), a hallucinogen, has increased both in Europe and the United States.1 This substance is manufactured in illicit laboratories from a variety of organic ketone precursors. MDMA, which is structurally related both to the stimulant amphetamine and to the hallucinogen mescaline, promotes the release of both...

Chemistry and Pharmacology of Hallucinogens, Entactogens and Stimulants

Pharmacopsychiatry July 1, 1998 K.-A. Kovar 32 citations

Amphetamines, tryptamines, phencyclidines, tetrahydrocannabinol and substances of the ecstasy group are characterized as stimulants, hallucinogens and entactogens. The various effects of each group and their mode of action in different transmitter systems are described. 28 new compounds of the amphetamine and tryptamine series has been calculated, which exceed the hallucinogenic effects of...

Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action

Drug and Alcohol Dependence June 1, 1998 Gerard J. Marek, George K. Aghajanian 39 citations

The psychedelic hallucinogens are comprised of three different groups of compounds according to Ž . Ž . their chemical structure Fig. 1 : 1 the ergolines Ž which contain an indole moiety e.g. lysergic acid . Ž . diethylamide, LSD ; 2 simple indoleamine hallucinoŽ gens e.g. N,N-dimethyltryptamine, DMT and psilocy. bin which share an indoleamine structure with the Ž endogenous neurotransmitter...

Ecstasy induced pneumomediastinum.

Thorax September 1, 1996 K. Rezvani, Arvinder S Kurbaan, D. Brenton 19 citations

Two cases are reported of pneumomediastinum induced by the use of Ecstasy, a semi-synthetic hallucinogenic compound related to amphetamine and mescaline which has become established as a recreational drug in the UK since the late 1980s. Both cases recovered without incident, but it is important that the possible complications of this drug be publicised so that at risk subjects can be diagnosed...

Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups

Journal of Medicinal Chemistry 1996 Aaron Monte, Danuta Marona‐lewicka, Matthew Parker et al. 106 citations

Tetrahydrobenzodifuran functionalities were employed as conformationally restricted bioisosteres of the aromatic methoxy groups in prototypical hallucinogenic phenylalkylamines 1 and 2. Thus, a series of 8-substituted 1-(2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoal kanes (7a-e) were prepared and evaluated for activity in the two-lever drug discrimination paradigm in rats trained...

Human psychopharmacology of N,N-dimethyltryptamine

Behavioural Brain Research December 1, 1995 Rick J. Strassman 257 citations

We generated dose-response data for the endogenous and ultra-short-acting hallucinogen, N,N-dimethyltryptamine (DMT), in a cohort of experienced hallucinogen users, measuring multiple biological and psychological outcome measures. Subjective responses were quantified with a new rating scale, the HRS, which provided better resolution of dose effects than did the biological variables. A tolerance...

Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA)

Behavioural Pharmacology April 1, 1995 Lisa E Baker, Jonathan M. Broadbent, E. K. Michael et al. 52 citations

The discriminative stimulus effects of the stereoisomers of 3,4-methylenedioxymethamphetamine (MDMA) were studied in rats trained to discriminate 1.25mg/kg of (+)-MDMA or 3.5mg/kg of (-)-MDMA from saline, in a two lever, water-reinforced, drug discrimination situation. The isomers of MDMA and 3,4-methylenedioxyamphetamine (MDA) substituted completely for both training drugs. The stimulants...

Increasing Use of “Ecstasy“ (MDMA) and other Hallucinogens on a College Campus

Journal of American College Health May 1, 1994 Michael J. Cuomo, Paul G. Dyment, Victoria M. Gammino 82 citations

We conducted a random survey of illicit drug use by undergraduate students at a private southern university in 1990 and compared the results with results from a similar 1986 survey of that college's student population. During the 4 years since the first study, the prevalence of cocaine use declined from 39% to 21%, and use of traditional amphetamines declined from 22% to 12%. No significant...